South Korea to resume wider use of AstraZeneca COVID-19 vaccine, exclude people under 30

South Korea to resume wider use of AstraZeneca COVID-19 vaccine, exclude people under 30

South Korea starts first vaccinations for senior citizens
South Korean senior citizens receive their first dose of the Pfizer-BioNTech COVID-19 vaccine at a vaccination centre in Seoul, South Korea on Apr 1, 2021. (Photo: Reuters/Chung Sung-jun)

SEOUL: South Korean authorities said on Sunday (Apr 11) they will move ahead with a COVID-19 vaccination drive this week, after deciding to continue using AstraZeneca's vaccine for all eligible people 30 years old or over.

South Korea on Wednesday suspended providing the AstraZeneca shot to people under 60 as Europe reviewed cases of blood clotting in adults.

People under 30 will still be excluded from the vaccinations resuming on Monday because the benefits of the shot do not outweigh the risks for that age group, the Korea Disease Control and Prevention Agency (KDCA) said in a statement.

Three vaccinated people in South Korea are reported to have developed blood clots, with one case determined to be correlated to the vaccine, Choi Eun-hwa, chair of the Korea Advisory Committee on Immunisation Practices, told a briefing.

That case was a type of blood clot considered less serious than the type being examined by European authorities, she said.

READ: South Korea orders closure of nightclubs, karaoke bars amid concern over fourth COVID-19 wave

For most people, the risks of COVID-19 are far worse than the rare possibility of side effects from the vaccines, Choi said, adding that the best way to end the pandemic was to vaccinate everyone who can receive it.

But she said, "the benefits are not as great for those under 30 years old, so we will not recommend the AstraZeneca vaccine for them.".

The AstraZeneca shot’s benefit-to-risk ratio rises the older people get as the risk of serious harm due to vaccination falls and ICU admissions prevented by vaccination rise sharply, according to the University of Cambridge’s Winton Centre for Risk and Evidence Communication.

The drugmaker has said its studies have found no higher risk of clots because of its vaccine, millions of doses of which have been administered worldwide. The World Health Organization has said the benefits outweigh the risks.

Global controversy over the efficacy and side-effects of some COVID-19 vaccines has caused some delays in South Korea’s vaccination campaign, which kicked off in late February with the goal of reaching herd immunity in November.

The second-quarter vaccination programme includes special disability school teachers and vulnerable groups, including people with disabilities and the homeless, the KDCA said.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram​​​​​​

Source: Reuters/zl

Bookmark